8-K: BIOLASE Reports Q1 2024 Results, Reaffirms Full-Year Guidance Amidst Increased Laser Adoption

BIOLASE reported its first quarter 2024 financial results, showing increased adoption of dental lasers and improved cost structure, while reiterating its full-year revenue growth and profitability guidance.

Summary

• BIOLASE announced its financial results for the first quarter of 2024, ending March 31, 2024.
• The company saw a 3% decrease in net revenue compared to the same quarter last year, with revenue totaling $10.1 million.
• U.S. laser revenue decreased by 22% year-over-year, while international laser revenue decreased by 12%.
• Consumables revenue increased by 17% in the U.S. and 8% internationally year-over-year.
• Gross margin improved slightly to 33% from 32% in the same quarter last year.
• Operating expenses decreased by 9% year-over-year to $7.9 million.
• The operating loss improved by 15% year-over-year to $4.5 million.
• The company's adjusted EBITDA loss decreased by 21% year-over-year to $3.5 million.
• BIOLASE reiterated its full-year 2024 guidance, expecting a 6% to 8% increase in net revenue, reaching between $52 million and $53 million, and positive adjusted EBITDA for the full year.
• Approximately 67% of U.S. Waterlase sales came from new customers, and 42% from dental specialists.
• The company had cash and cash equivalents of approximately $6.4 million on March 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the improved cost structure, increased adoption of lasers, and reaffirmed full-year guidance, despite a slight decrease in revenue. The company is showing progress towards profitability.

Positives

• Consumable sales increased by 14% year-over-year, marking the third strongest quarter in company history.
• Gross margin improved by 1% year-over-year and 7% sequentially, benefiting from in-house trunk fiber supply and inventory adjustments.
• Operating expenses decreased by 9% year-over-year.
• Operating loss improved by 15% year-over-year.
• The company has strengthened its balance sheet to support growth opportunities.
• The company is seeing increased adoption of its lasers, with a significant portion of sales coming from new customers and dental specialists.

Negatives

• Net revenue decreased by 3% compared to the same quarter last year.
• U.S. laser revenue decreased by 22% year-over-year.
• International laser revenue decreased by 12% year-over-year.
• The company reported a net loss of $6.5 million, or $0.36 per share.
• The company had an adjusted EBITDA loss of $3.5 million, or $0.20 per share.

Risks

• The company faces a challenging business environment that could offset the continued adoption of lasers and consumables.
• There is uncertainty regarding customer acceptance of new product offerings and market changes.
• The company faces risks associated with managing the growth of the business.
• The company's ability to continue as a going concern is subject to substantial doubt.
• The company is subject to competitive factors including pricing pressures and new product introductions.

Future Outlook

BIOLASE reiterates its full-year 2024 financial guidance, expecting a 6% to 8% increase in net revenue to between $52 million and $53 million, and positive Adjusted EBITDA for the full year.

Management Comments

• John Beaver, President and Chief Executive Officer of BIOLASE, stated that the increased adoption of their lasers is an encouraging sign.
• Management believes that their actions have significantly improved operations, expanding gross margin and reducing expenses.
• Management believes that these initiatives and revenue expansion plans position BIOLASE for success.
• Management also stated that they have strengthened the balance sheet to maximize growth opportunities and enhance shareholder value.

Industry Context

The dental laser market is competitive, with companies vying for adoption by general dentists, specialists, and group practices. BIOLASE's focus on new customer acquisition and consumable sales aligns with industry trends towards recurring revenue models. The company's emphasis on cost reduction and operational efficiency is also a common theme in the medical device sector.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, BIOLASE's focus on laser technology places it in competition with companies like Convergent Dental (Solea laser) and Fotona (Lightwalker laser).
• BIOLASE's reported 67% of U.S. Waterlase sales coming from new customers suggests a strong push for market penetration, which is a key metric for growth in the medical device industry.
• The 14% year-over-year increase in consumable sales indicates a positive trend in recurring revenue, which is often a focus for medical device companies.
• The company's goal of achieving positive adjusted EBITDA for the full year is a common benchmark for profitability in the industry.
• The company's gross margin of 33% is a key metric to compare against competitors in the dental laser space.

Stakeholder Impact

• Shareholders may be encouraged by the reaffirmed full-year guidance and improved cost structure.
• Employees may be impacted by the cost reduction initiatives.
• Customers may benefit from the company's focus on innovative laser technology.
• Suppliers may be impacted by the company's in-house trunk fiber supply.

Next Steps

• BIOLASE will host a conference call to discuss the results and answer questions.
• The company will continue to focus on increasing adoption of its lasers and consumables.
• The company will continue to execute its cost reduction initiatives.
• The company will continue to focus on maximizing growth opportunities and enhancing shareholder value.

Key Dates

Keywords

dental lasers, BIOLASE, financial results, revenue growth, EBITDA, consumables, laser technology, medical devices, dental industry